A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis
Public ClinicalTrials.gov record NCT04729621. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal Osteoporosis
Study identification
- NCT ID
- NCT04729621
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Enrollment
- 332 participants
Conditions and interventions
Conditions
Interventions
- Prolia® Combination Product
- TVB-009 Combination Product
Combination Product
Eligibility (public fields only)
- Age range
- 60 Years to 90 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 21, 2021
- Primary completion
- Dec 30, 2022
- Completion
- Jun 18, 2023
- Last update posted
- Apr 17, 2024
2021 – 2023
United States locations
- U.S. sites
- 20
- U.S. states
- 8
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Site 103 | Phoenix | Arizona | 85004 | — |
| Teva Site 119 | Tucson | Arizona | 85704 | — |
| Teva Site 118 | San Diego | California | 92111 | — |
| Teva Site 107 | New London | Connecticut | 06320 | — |
| Teva Site 115 | Coral Gables | Florida | 33134 | — |
| Teva Site 114 | Edgewater | Florida | 32132 | — |
| Teva Site 116 | Lake City | Florida | 32055 | — |
| Teva Site 109 | Miami Lakes | Florida | 33014 | — |
| Teva Site 117 | Miami Springs | Florida | 33166 | — |
| Teva Site 110 | Oldsmar | Florida | 34677 | — |
| Teva Site 120 | Orlando | Florida | 32801 | — |
| Teva Site 102 | Ormond Beach | Florida | 32174 | — |
| Teva Site 101 | Port Saint Lucie | Florida | 34952 | — |
| Teva Site 111 | Sarasota | Florida | 34239 | — |
| Teva Site 104 | Tamarac | Florida | 33321 | — |
| Teva Site 112 | Henderson | Nevada | 89014 | — |
| Teva Site 113 | North Las Vegas | Nevada | 89030 | — |
| Teva Site 105 | Albuquerque | New Mexico | 87106 | — |
| Teva Site 108 | Duncansville | Pennsylvania | 16635 | — |
| Teva Site 106 | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04729621, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 17, 2024 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04729621 live on ClinicalTrials.gov.